Aclarion Inc., a Broomfield-based healthcare technology company, said June 3 it has signed an agreement with the Los Angeles-based Institute of Neuro Innovation to expand use of its Nociscan platform and generate additional real-world clinical evidence. The Nasdaq-listed company said the partnership will bring Nociscan to the neuroscience group led by neurosurgeon Dr. Amir Vokshoor, while also supporting a study comparing Nociscan’s pain-related chemical biomarker data with bone metabolic information from SPECT-CT in patients with chronic low back pain.
Why this is relevant to businesses in Jefferson County:
- Aclarion is based in neighboring Broomfield, part of the broader northwest metro economy tied closely to Jefferson County employers, investors and healthcare providers.
- The expansion signals growth for a Front Range medical technology company developing commercial-stage software and diagnostic tools, a sector with regional economic importance.
- New clinical evidence and market expansion can strengthen the company’s prospects for adoption, partnerships and future hiring across the Denver-area life sciences ecosystem.
For Jefferson County’s business community, the announcement is most significant as a sign of continued momentum in the region’s health-tech and bioscience corridor. While the new clinical site is in Southern California, the deal reflects commercialization progress for a company headquartered just outside Jefferson County and operating within the same metropolitan talent, capital and healthcare network that includes Lakewood, Arvada, Golden and other Jeffco communities.
Aclarion describes Nociscan as a software-as-a-service platform that uses magnetic resonance spectroscopy, biomarker analysis and artificial intelligence tools to help physicians identify which lumbar discs are likely causing chronic low back pain. The company says the technology is designed to give doctors more precise diagnostic information than conventional imaging alone, potentially helping guide treatment decisions and improve outcomes.
The Institute of Neuro Innovation partnership does more than add another site using the technology. Aclarion said it also will contribute to a growing body of real-world evidence by evaluating how Nociscan’s disc-level biomarker analysis may work alongside SPECT-CT, which measures bone metabolic activity. For emerging medical technology companies, that kind of evidence generation can be crucial in winning broader physician adoption and support from payers.
The development may be especially noteworthy for metro Denver stakeholders watching commercialization of locally connected public companies. Aclarion said the agreement supports its scalable growth strategy while building data assets considered critical for provider and payer adoption. If the company continues to expand clinical partnerships and validate outcomes, it could further raise the profile of the region’s medical innovation economy.
Although the immediate operational impact on Jefferson County is indirect, the announcement is still newsworthy locally because it points to outside-market expansion by a nearby healthcare technology firm—often an early indicator of revenue opportunity, investment interest and broader ecosystem growth along the Front Range.
Source: Press Release
